Literature DB >> 15161075

Comparison of different routes of vaccination for eliciting antibody responses in the human stomach.

Eva-Liz Johansson1, Charlotta Bergquist, Anders Edebo, Camilla Johansson, Ann-Mari Svennerholm.   

Abstract

Determination of optimal routes to induce mucosal immune responses locally in the stomach and duodenum are important steps in the development of vaccines against Helicobacter pylori infection. In this study, we immunized H. pylori-infected individuals either nasally or rectally with a model antigen, i.e. cholera toxin B subunit, and compared the immune responses after these routes with the responses after oral or intrajejunal vaccination. Specific antibody levels in serum as well as specific antibody levels and antibody-secreting cells in biopsies from antrum and duodenum were determined by ELISA and ELISPOT methods. In contrast to oral vaccination, nasal and rectal vaccination did not induce significant increases in specific antibody-secreting cells either in the antrum or duodenum. Furthermore, when analyzing the antibody levels in saponin extracted biopsies, intrajejunal vaccination was superior to both nasal and rectal vaccination in inducing antigen-specific IgA levels in the stomach. We conclude that oral vaccination is the optimal route for induction of antigen-specific IgA antibody responses in the stomach and duodenum of humans, while nasal or rectal vaccination is less suitable for this purpose.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15161075     DOI: 10.1016/j.vaccine.2003.09.002

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  15 in total

1.  Intranasal vaccination with the recombinant Listeria monocytogenes ΔactA prfA* mutant elicits robust systemic and pulmonary cellular responses and secretory mucosal IgA.

Authors:  Jin Qiu; Lin Yan; Jianbo Chen; Crystal Y Chen; Ling Shen; Norman L Letvin; Barton F Haynes; Nancy Freitag; Lijun Rong; James T Frencher; Dan Huang; Xunming Wang; Zheng W Chen
Journal:  Clin Vaccine Immunol       Date:  2011-01-26

Review 2.  Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens.

Authors:  Douglas S Watson; Aaron N Endsley; Leaf Huang
Journal:  Vaccine       Date:  2012-02-02       Impact factor: 3.641

3.  Intranasal immunization with an epitope-based vaccine results in earlier protection, but not better protective efficacy, against Helicobacter pylori compared to subcutaneous immunization.

Authors:  Haibo Li; Jinyong Zhang; Yafei He; Bin Li; Li Chen; Weiwei Huang; Quanming Zou; Chao Wu
Journal:  Immunol Res       Date:  2015-07       Impact factor: 2.829

Review 4.  Intranasal immunization with dry powder vaccines.

Authors:  Tania F Bahamondez-Canas; Zhengrong Cui
Journal:  Eur J Pharm Biopharm       Date:  2017-11-06       Impact factor: 5.571

5.  Intrarectal immunization with rotavirus 2/6 virus-like particles induces an antirotavirus immune response localized in the intestinal mucosa and protects against rotavirus infection in mice.

Authors:  Davide Agnello; Christine A Hervé; Amandine Lavaux; Magali Darniot; Patrice Guillon; Annie Charpilienne; Pierre Pothier
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

6.  Sublingual immunization protects against Helicobacter pylori infection and induces T and B cell responses in the stomach.

Authors:  Sukanya Raghavan; Anna Karin Ostberg; Carl-Fredrik Flach; Annelie Ekman; Margareta Blomquist; Cecil Czerkinsky; Jan Holmgren
Journal:  Infect Immun       Date:  2010-08-09       Impact factor: 3.441

Review 7.  Pathogenesis of Helicobacter pylori infection.

Authors:  Johannes G Kusters; Arnoud H M van Vliet; Ernst J Kuipers
Journal:  Clin Microbiol Rev       Date:  2006-07       Impact factor: 26.132

8.  Helicobacter pylori: bacterial factors and the role of cytokines in the immune response.

Authors:  Tania Beatriz Romero-Adrián; Jorymar Leal-Montiel; Francisca Monsalve-Castillo; Edgardo Mengual-Moreno; Ernesto García McGregor; Lenis Perini; Ana Antúnez
Journal:  Curr Microbiol       Date:  2009-10-22       Impact factor: 2.188

9.  Intranasal immunization with Gal-inhibitable lectin plus an adjuvant of CpG oligodeoxynucleotides protects against Entamoeba histolytica challenge.

Authors:  Catherine P A Ivory; Kris Chadee
Journal:  Infect Immun       Date:  2007-07-09       Impact factor: 3.441

Review 10.  Non-Reflex Defense Mechanisms of Upper Airway Mucosa: Possible Clinical Application.

Authors:  H Pedan; V Janosova; A Hajtman; V Calkovsky
Journal:  Physiol Res       Date:  2020-03-27       Impact factor: 1.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.